On the other hand, a multivariate analysis revealed that KRAS mutation, but not NRAS mutation, was an adverse independent prognostic factor in the cohort of patients with cytogenetically normal AML but not in the whole cohort of AML patients [89]. This evidence concerns the gene NRAS and acute myeloid leukemia.